You have 9 free searches left this month | for more free features.

lambrolizumab

Showing 1 - 25 of 200

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Houston (other, biological, procedure)

Active, not recruiting
  • Recurrent Glioblastoma
  • Recurrent Gliosarcoma
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 19, 2022

Lung Non-Small Cell Carcinoma Trial in Buffalo (Pembrolizumab)

Active, not recruiting
  • Lung Non-Small Cell Carcinoma
  • Pembrolizumab
  • Buffalo, New York
    Roswell Park Cancer Institute
Jan 27, 2023

Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

Active, not recruiting
  • Follicular Lymphoma
  • +2 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 6, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Houston

Terminated
  • Locally Advanced Malignant Solid Neoplasm
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 22, 2022

Melanoma Trial in Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Knoxville, Tennessee
    University of Tennessee Medical Center
Dec 20, 2022

Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial in Chicago

Terminated
  • Pancreatic Adenocarcinoma
  • +2 more
  • Pembrolizumab
  • Wild-type Reovirus
  • Chicago, Illinois
    Northwestern University
Sep 6, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 Trial in San Francisco (Pembrolizumab,

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Prognostic Stage IV Breast Cancer AJCC v8
  • Pembrolizumab
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 5, 2023

Metastatic Malignant Tumor in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma Trial in

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Bone
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
Jan 4, 2023

Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Jacksonville (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +3 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Jan 3, 2023

Colorectal Tumors, Microsatellite Instability Trial in Milano, Rozzano (temozolomide (induction),, pembrolizumab (treatment))

Recruiting
  • Colorectal Neoplasms
  • Microsatellite Instability
  • temozolomide (induction),
  • pembrolizumab (treatment)
  • Milano, Italy
  • +3 more
Sep 28, 2022

Thymoma, Thymic Cancer Trial in Houston (Pembrolizumab)

Recruiting
  • Stage III Thymoma AJCC v8
  • +6 more
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 11, 2022

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Malignant Solid Neoplasm
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)

Recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Mar 22, 2022

Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8 Trial in Houston

Active, not recruiting
  • Stage I Bladder Cancer AJCC v8
  • +4 more
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Oct 20, 2022

Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in

Recruiting
  • Advanced Hepatocellular Carcinoma
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 30, 2023

Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma Trial in Seattle

Terminated
  • Advanced Hepatocellular Carcinoma
  • +2 more
  • Cabozantinib S-malate
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 12, 2022

Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression Trial in Portland (drug, other,

Active, not recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Sep 26, 2022

Thymic Carcinoma Trial in Columbus (other, biological, drug)

Recruiting
  • Thymic Carcinoma
  • Laboratory Biomarker Analysis
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 27, 2022

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Melanoma Trial in Orlando, Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Orlando, Florida
  • +1 more
Jul 5, 2022

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial (radiation, biological, procedure)

Withdrawn
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
  • Copper Cu 64-DOTA-pembrolizumab
  • +2 more
  • (no location specified)
Jun 7, 2022

Hormone-Resistant Prostate Cancer, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Soft Tissues Trial

Active, not recruiting
  • Hormone-Resistant Prostate Cancer
  • +6 more
  • Pembrolizumab
  • pTVG-HP Plasmid DNA Vaccine
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Nov 8, 2022

Colorectal Cancer, Colorectal Cancer Metastatic Trial in United States (Pembrolizumab, Regorafenib)

Active, not recruiting
  • Colorectal Cancer
  • Colorectal Cancer Metastatic
  • Duarte, California
  • +3 more
Aug 5, 2022